ARCHIVES

Highlights of NCDDGs: 3 Drugs on Market, 12 in Development; Advisors Approve Plan to Issue $10.5 Million Contract For Pediatric Preclinical Testing Program

This article is from The Cancer Letter archive.

Vol. 28 No. 44 | November 29, 2002

Download PDF Visit The Full Archive

Related Articles

Clinical Trials: “Master Protocol” To Rely On Biomarkers In Testing Multiple Lung Cancer Agents

November 15, 2013

In Brief: House Passes FY ’77 Money Bill, But Veto Seems Likely; NIH Relaxes Moonlighting Rule

August 20, 1976

FDA Ceases Exclusion Of Women From Early Drug Studies

May 7, 1993

Manville Sues U.S. Over “Withheld” Wartime Data

July 22, 1983

Economic Analyses Of New Therapies Useful In Phase III Studies, Trialists Say

July 24, 2009

Cancer Advocacy: Deal Returns $3M to Office of Women’s Health, Spends $3.5M On Workshops

August 1, 1997